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Abstract 
 
Within this dissertation the topic of virtual screening is discussed with regard to 
three different cancer targets and also a brief introduction of the tools used in virtual 
screening.  In Chapter 1, the reader will be introduced to virtual screening and the 
programs that are used in virtual screening.  In Chapter 2, the first of three projects are 
discussed.  This project consists of the work that was done to find inhibitors of the P53 
binding domain of MDMX.   In this project the mobility of residues within the binding 
site of MDMX are discussed and the ways in which we attempted to model how drugs 
would bind two adjacent pockets within MDMX.  In Chapter 3, the virtual screening and 
modeling work done for RING domain of MDM2 and MDMX is discussed.  This work 
was done in conjunction with Moffitt Cancer Center in order to solve the 60 year old 
mystery of the mechanism of how thalidomide and possibly its analog lenalidomide 
caused children to be born limbless.  Current thinking is that Cereblon through an 
unknown teratogenic mechanism activates an increase in FGF8.  We suggest a 
mechanism that may happen in parallel that involves stabilization of MDM2 and the 
reduction of P63 levels.  Chapter 4, the work that was done against the BH3 binding 
domain of MCL-1 is discussed in conjunction with collaboration with the Manetsch lab.  
In order to complete this screening the validation of IC50 values and then attempt to 
modify those products based upon the structure of MCL-1.  Chapter 5 discusses the work 
done to find inhibitors of deoxycytidine kinase. All of these chapters taken together 
! ix!
provide a brief overview of the computational work done produce inhibitors of Protein-
Protein Interaction against three major cancer targets. 
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Chapter 1:  Virtual Screening in Drug Discovery 
 
This chapter will serve as a brief introduction to the tools available in a drug discovery 
program. 
  
1.1 Introduction 
Screening of new compounds is an important part of any drug discovery program.  
Screening generally involves purchasing molecular libraries, quantifying protein binding 
of those molecules, and some discernment and investigation into the properties that 
positively or negatively affect said binding.  Finding weak binders amongst a large 
library of compounds is a tedious and difficult task, but is central to finding “hits”, 
molecules which show some activity against a protein of interest, and is the central task 
of screening.  Screening results typically find 0 – 3% hits almost none of which will 
contribute to what eventually become lead compounds.  Lead compounds are generally 
medium to strong binders with a specificity and IC50 that begin to approach marketable 
drug levels.  The research that occurs between screening, hit, and lead compound is 
largely the realm of the medicinal chemist and biologist.  A considerable amount of time 
and funding occurs during this period, a period that can be greatly accelerated through 
computational methods, namely virtual screening.  Virtual screening involves techniques 
that are analogous to traditional screening methods. Figure 1 outlines the process in 
silico.(Rester, 2008) 
! 2!
 
Figure 1 Computational methods including virtual screening fit well with the 
beginning of a drug discovery project, and especially during target selection and 
validation, hit/lead finding, and lead optimization. 
Virtual screening can reduce the burden on medicinal chemists and structural 
biologists by rapidly and relatively inexpensively screening larger libraries than what 
would be possible in vitro.  Large libraries from various sources including the National 
Center for Biotechnology Information and structures available through the protein 
databank, both NMR and X-ray crystals, are vital for a virtual screening program.  
Virtual screening consists largely of molecular docking, a simulation of protein binding 
of library compounds to the proteins of interest.  There are five essential steps in the 
virtual screening process:  ligand preparation, protein preparation, pose search (molecular 
docking), pose scoring (molecular docking), and data analysis.  Each of these parts has a 
myriad of available options and techniques, each with its own benefits and downsides.  
There is a long list of techniques which can support a screening program such as 
molecular modeling, homology modeling, molecular dynamics, 2D and 3D QSAR 
! 3!
screening, pharmacophore screening, ab initio quantum mechanics, both ligand and 
structure based drug design, and fragment or combinatorial based screening to name a 
few.  All together these techniques and methodologies attempt to achieve many of the 
same goals as in vitro high throughput screening. 
!
Figure 2 Molecular Docking follows the above procedure. Listed to the right in 
green are the programs that are used by my group. 
 
The first virtual screening program was DOCK, which was released by Tack 
Kuntz’s group at University of California at San Francisco in 1982.  Since then, both 
academic and corporate groups have released time more than 16 different molecular 
docking programs including DOCK, AutoDock, Glide, GOLD, FlexX to name a few, 
Table 1.  A particular issue with having so many molecular docking or virtual screening 
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programs is that each has a specific instance where it is the most predictive program.  All 
perform similar functions and give an output that is in the form of one or more ligand 
conformations within a defined binding site area and a docking score.  This output cannot 
at this time be used blindly because scoring functions, despite a long and involved 
evolution, still have large amounts of error.  Often, very similar molecules will have 
wildly different scores despite being able to reproduce a known conformation.  The pose, 
conformation of the ligand in the appropriate orientation, then becomes very important 
and being able to visually inspect each conformation proves very valuable, especially 
when considering pharmacophore design and discerning Structure Activity Relationships 
(SAR). 
Table 1 Table of Major Docking Programs 
Company Molecular Docking Program 
Scripps 
UCSF 
BioSolveIt 
Schrodinger 
CambridgeSoft 
AutoDock 
Dock 
FlexX 
GLIDE 
GOLD 
 
1.2 Ligand Preparation 
Potential ligands can come from many different sources including libraries from chemical 
companies, libraries from National Institutes of Health (NIH), libraries from medicinal 
chemists or combinatorially derived libraries.  The National Institutes of Health have one 
particularly useful set of compounds known as the NCI Diversity Set.  The NCI diversity 
set is a subset of the 140,000 compounds available from NCI as part of the NCI plated 
set.  The purpose of this set of compounds is to provide a diverse library of chemical 
structures. The NCI diversity set of compounds was created by taking all of the 
compounds in the NCI plated compounds.  Reducing them based upon their ability to 
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fulfill orders of the compounds that lead to the selection of around 76 thousand 
compounds.  These compounds were then aligned based upon a three point 
pharmacophore with each point representing a particular interaction.  Over a million 
possible pharmacophores were produced but then determining whether the conformations 
were of an acceptably low energy reduced this further.  Compounds were then selected 
on whether they added at least 5 more pharmacophores to the diversity set.  This lead to 
an initial set of 1990 compounds which known as NCI Diversity Set I.  This set of 
compounds has undergone 3 revisions and is subject to change as compounds that make 
up the diversity set become unavailable.  This has resulted in a drop in the number of 
compounds from 1990 compounds to 1597 compounds.  In other parts of this document, 
the revision will be noted after the name Diversity Set such as Diversity Set II*. 
Table 2 Revisions of NCI Diversity Set and the number of ligands contained in each. 
NCI Diversity Set Revision Structures 
NCI Diversity Set I 
NCI Diversity Set II 
NCI Diversity Set III 
1990 
1564 
1597 
 
Combinatorial techniques can be used to create a diverse set of compounds from a 
set of fragments or from a group of ligands. In combinatorial screening, both the scaffold, 
also known as the core, can be altered as well as functional groups or attachments.  
BREED, a script within the Schrödinger Software Suite, is another type of combinatorial 
technique, which involves overlaying docked compounds and matching areas of overlap 
and exchanging atoms and even entire functional groups.  BREED tolerates some 
difference in angle and distance when calculating overlap.  Both produce new libraries of 
compounds, although combinatorial methods offer the researcher more control.(Pierce, 
Rao, & Bemis, 2004) 
! 6!
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Figure 3 Pictured here is a small molecule (gray) which has been modified via 
CombiGlide(Schrödinger, 2011) and now interacts with an additional binding 
pocket. 
The importance of screening a diverse set of ligands lies in that the chemical space of 
small compounds is vast.  As of July 2009, 49 million compounds have been reported in 
the scientific literature, and there is an approximate theoretical limit of approximately 
1060 possible small organic molecules.(Bohacek, McMartin, & Guida, 1996; Dobson, 
2004)  The space encompassed by chemical space is so large that it would be physically 
impossible to produce every molecule possible.   There are 1082 atoms in the 
universe(Villanueva, 2009) and the vast majority of those atoms are either helium or 
hydrogen as contained within the stars.  The ratio of carbon to hydrogen atoms in the 
universe is 2.37 x 10-4 M.(Croswell, 1995)  It would take many billions of years of fusion 
within the stars to produce a ratio of carbon necessary to produce even one percent of the 
possible compounds.  Even with no timetable to finish the conversion, the energy 
required to fuse hydrogen into carbon would be phenomenal.  It would necessary to 
! 7!
produce at least a 10 µM solution or 6.04 x 1018 of each molecule per milliliter for 
screening.  If the right proportion of carbon, nitrogen, and oxygen were achieved, it might 
take 10 to 20 universes to make enough material to screen every small molecule once!  It 
may be possible to screen a significant portion of these compounds via in silico screening 
in the near future.  If Moore’s law holds true, 2000 compounds on single processor in 3 to 
4 hours today would become 3.35 x 1082 on a single processor in 3 to 4 years in just 25 
years using today’s screening methods.(Brock & Moore, 2006)  With large 
multiprocessor computers or computational clusters, screening all possible small 
molecules will become possible even sooner. 
 
1.3 Protein Preparation 
The contribution of structural biology to the field of computational chemistry cannot be 
overstated.  With X-ray crystal protein structures or NMR protein structures, it becomes 
very difficult to have a virtual screening program.  In the absence of a protein, with a 
large library of known inhibitors ligand based screening can be conducted where known 
activities are matched to ligands via 3D Quantitative SAR (QSAR) in an attempt to 
develop a pharmacophore with which to screen against. There are several kinds of QSAR 
that can be done computationally.  The number dimensions may refer to spatial 
dimensions or refer to a set of attributes of considerations.  For instance, 1D QSAR is not 
a QSAR in one-dimensional space but QSAR developed using a parameter such as Log 
P.  3D QSAR does in fact refer to the three dimensional coordinates of a overlaid drug 
molecules from which structural motifs such as hydrogen bond donor or acceptor and 
hydrophobic residues become apparent.  In order for the overlapping structures to be 
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given meaning, they must be understood in the context of empirically derived 
activity.(Verma, Khedkar, & Coutinho, 2010)  
In addition to this technique, if a similar protein exists, homology modeling can 
be used to build protein structure using another closely related structure as a template.  
Because protein structures are dynamic mobile molecules, it is helpful to have many 
different conformers of the same protein.  Screening against many conformers is a way to 
take into account protein flexibility and a way to gain a consensus of the best ligand 
conformations that best represent the in silico or in vivo experiment.  A consensus can be 
made through averaging of scores or creating clusters of very close scores. 
Proteins are made available through the Protein Data Bank (rcsb.org)(Berman et 
al., 2000; Bernstein et al., 1977) in the form .pdb files.  Crystallographers and NMR 
structural biologists deposit these files along with the related academic papers as a 
requirement to publish.  These .pdb files cannot be used directly and the data must go 
through significant processing before being used to screen.  The resolution of the X-ray 
diffraction method is too low to detect chemical features like hydrogen atom positions 
and because proteins are flexible, there is some variability to the position of side chains 
making it difficult to process X-ray diffraction data.  Bond information is not explicitly 
contained within the .pdb file either and is inferred from inter-atomic distances.  Missing 
information must be derived using protein prediction programs such as Prime from 
Schrödinger.(Andrec, Harano, Jacobson, Friesner, & Levy, 2002) 
 
! 9!
1.4 Docking Methods (Search Algorithms) 
The goal of conformational search within a docking protocol is to find the pose 
that most accurately represents the interactions found in vivo.  One way to check the 
accuracy of this search is to compare root mean square deviation (R.M.S.D.) with an 
available crystal structure and molecular dynamics can be used to test the stability of a 
protein confirmation as well.  Large discrepancies between the X-ray crystal coordinates 
and the processed protein coordinates should be avoided because the X-ray coordinates 
represent empirically derived information that is the closest to in vivo structures.  When 
this is done using both the ligand and protein from a single crystal structure, this is called 
self-docking.  Most virtual screening programs are developed to screen novel molecules 
for which the activity is unknown. 
There are many approaches to search algorithms in molecular docking.  Listed 
here are approaches to conformational sampling.  Along with conformational sampling 
rotational and orientational sampling are done.  Rotational and orientational sampling 
occur prior to conformational sampling and is done at an optimized level representative 
of the possible rotational and orientational positions possible.(Goodsell & Olson, 1990)  
It would be impossible to sample at every angle and every point in space. 
A full search, a so called systematic grid search will sample more conformational 
space but takes so long that it is not reasonable for screening anything but a handful of 
compounds at a time.  Furthermore within the full population of conformations of any 
given ligand, most conformations will be unwanted, having unlikely and energetically 
unfavorable interactions.  To remedy this potential waste of computational power, several 
methods have been devised including genetic algorithms, favorable interaction search, 
! 10!
and simulated annealing, a modification of a technique used in molecular dynamics 
where the ligand in this case would be heated and cooled in order to sample 
conformational space.(Lipkowitz & Boyd, 1990) 
Genetic algorithms search conformational space by mimicking natural selection 
by creating candidate solutions that are organized in a genetic representation and allowed 
to exchange information in a genetic way.  Genetic means that a random mixing of 
elements from previous solutions produces each subsequent solution.  These newly 
produced populations of solutions are then evaluated by a fitness function, a function 
which assigns a score in an attempt to rank poses by lowest energy, validity, or other 
metric.(Lipkowitz & Boyd, 1990) 
Incremental construction attempts to match functional groups to favorable 
interactions and reconstruct the ligand by joining fragments.  A central node is chosen 
from the central fragments are then built from until the original molecule is constructed. 
The best solution is selected by evaluating each solution via a fitness function.  This is a 
methodology employed by FlexX.(Sato, Shewchuk, & Tang, 2006; Trott & Olson, 2010) 
A molecular dynamics approach can be used employing simulated annealing, 
which a molecular dynamics simulation in which alternating heating and cooling periods 
move ligands between potential energy wells.  This is one method that is part of the very 
popular molecular docking program AutoDock Vina.(Trott & Olson, 2010) 
Metropolis - Monte Carlo Methods are still the preferred methods when studying 
a few molecules and geometry is absolutely important. This method uses Markov chains 
to build a set of conformations that are representative of a population of conformations.  
! 11!
It is also one of the slowest methods.  Monte Carlo is very well suited for single molecule 
study.(Lipkowitz & Boyd, 1990) 
In addition to the above search mechanism, there exist hybrid methods, which 
attempt to optimize both speed and search completeness. Schrödinger’s Glide uses a 
hybrid of an exhaustive Monte Carlo search and favorable interaction search.  
Schrödinger refers to this as “greedy search” and involves an inverted pyramid like 
narrowing of conformations until only a few are reported.(Friesner et al., 2004; Friesner 
et al., 2006; Halgren et al., 2004) 
! 12!
!
Figure 4 Protein preparation proceeds from the top structure that was downloaded 
from the Protein Data Bank to the bottom structure, the prepared structure. 
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1.5 Molecular Docking (Scoring Functions) 
Scoring functions attempt to quantify binding and are related but not necessarily 
equivalent to the fitness functions that evaluate docking search solutions.  Results are 
typically reported in Kcal per mole as a measurement of binding affinity (i.e., binding 
free energy).  There are many scoring functions and more being created all the time.  The 
problem with using any particular scoring function is that it may fail in a particular case 
of interest.  For this reason it is often advisable to employ consensus scoring with many 
different scoring functions as possible. 
Scoring functions are generally of three types:  force field, empirical, and so-
called knowledge based methods.  Force Field based methods are derived from 
AMBER(Yang et al., 2006), CHARMM(Brooks et al., 2009),! or! OPLS(Kaminski,!Friesner,! Tirado?Rives,! &! Jorgensen,! 2000) force field non-bonded interaction terms 
including van der Waals and electrostatic terms.  Electrostatic terms are often 
complimented by Generalized Born equation term (GBSA) for calculating the effects of 
solvation.  This methodology is a part of the Dock program.(Lipkowitz & Boyd, 1990) 
Empirical functions are scoring functions that calculate an estimate of the free 
energy of binding by summing a list of interactions that are weighed by experimentally 
derived coefficients.  An interaction may be identified as an advantage or a penalty.  For 
example electrostatic interactions are then broken into hydrogen bonding, ionic 
interactions, and buried charge penalties.  GOLD further breaks hydrogen bonding into 
twelve separate categories that all have different constants associated with them.(Jones, 
Willett, Glen, Leach, & Taylor, 1997) 
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!
Figure 5 Selfdock of Nutlin-2 to MDM2.  Blue is from the crystal structure PDB ID: 
1RV1 and green is the pose obtained with GLIDE SP. 
So-called “Knowledge-based” scoring functions are simply scoring functions in 
which score is based upon how closely a novel ligand matches known binders contained 
within the Protein Data Bank. (Berman et al., 2000; Bernstein et al., 1977) 
Hybrid scoring functions such as the one employed in GLIDE use two or more 
functions to arrive at a score.  GLIDE’s Glidescore is both a force field and an 
empirically derived scoring function.  It takes electrostatic and van der Waals terms from 
a OPLS force field based score and modify it with advantages and penalties from an 
empirical based function.(Friesner et al., 2004; Friesner et al., 2006; Halgren et al., 2004) 
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Another way scoring functions can differ is whether they are all-atom based 
functions or employ a “grid,” a grid is a lattice of points within the binding site at which 
all interactions are accounted for at that point.  Scoring functions that employ a grid are 
twenty-fold faster than all atom based scoring functions.  They have the added benefit of 
being separable, as each can represent all of the interactions of the protein without having 
the ligand within the binding site.(Lipkowitz & Boyd, 1990) 
 
1.6 Data Analysis 
When analyzing the data from virtual screening, the most important thing to 
remember is that nothing can be considered in isolation.  The scoring functions as stated 
above are often accurate in a particular set of experiments and not predictive or able to 
correlate under a different set of conditions.  Visual inspection of the binding pose must 
be taken along with docking score in order to make the determination of how well a 
ligand binds to a target. 
The best ligands have a ligand efficiency of around 1.5 Kcal/heavy atom/mole.  
This quality of score is atypical to early screening near the beginning of a medicinal 
chemistry program.  Finding weak binders, or hits, takes a bit more interpretation and the 
identification of important functional groups and interactions. 
The docking scores attempt to predict the energy of binding and that energy 
should correlate with biophysical measurements in the form of IC50 values or Ki. 
!
Figure 6 This equation describes the simple relationship between Ki and IC50. 
! 16!
A two kilocalorie per mole difference in Glide docking score represents about a one order 
of magnitude difference in IC50 concentration. Two situations will arise where this is not 
the case: 1. All the ligands are extremely weak binders and then making it quite difficult 
to find a signal in the proverbial noise.  2.  The scoring function is poorly suited for the 
protein and ligand combinations being screened, and the researcher should consider using 
a different scoring function or obtaining consensus with another scoring function. 
 
1.7 Protein Flexibility 
Inclusion of protein flexibility is a relative new development in molecular 
docking which typically uses static proteins.  Using static proteins greatly reduces the 
computational cost of molecular docking but does not represent the reality of induced fit 
effects, the lock and key mechanism of ligand – protein interaction.  Not only can 
proteins have mobile side chains but can also have mobile domains.  One class of protein 
is in fact so mobile it is known as intrinsically disordered.  Intrinsically disordered 
proteins are some of the most difficult proteins to study because they are difficult to 
capture via x-ray crystallography.  Intrinsically disordered proteins represent some of the 
most important molecules however and include P53 and MDM2 proteins whose study 
holds the key to creating better cancer drugs.(Dunker & Uversky, 2010) 
One simple but crude way to consider protein flexibility is to dock to different 
conformations of a protein.  This is possible because of the wealth of structures now 
included in the protein data bank. The biggest problem with this way of considering 
protein flexibility is that it is probably not totally representative of the population of 
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conformations that occur naturally.  However, in order for crystallization to occur, the 
conformations must be of relatively low energy and structurally stable. 
Yet another way but still quite incomplete is to allow side chains to move partially 
or fully.  To fully appreciate the movement of a protein, either molecular dynamics or 
low frequency modes of vibration should be considered.  With either technique, several 
frames, or protein conformations, are produced which then can be docked to produce a 
docking ensemble. 
 
1.8 Conclusion 
As stated previously, the docking techniques presented here do not represent the 
totality of what is available and give a framework for understanding the rest of this 
dissertation.  The field of virtual screening is constantly changing and new techniques are 
being developed all the time.  One thing that guides the purpose of all these techniques 
are the simulation of natural phenomena using computational techniques, and one must 
never lose sight that although these techniques can be useful, they should never be taken 
without considering the empirical evidence that underlies the simulation. 
For most of the experiments included in this dissertation, the Schrödinger Suite of 
Software was used.  Maestro is the molecular modeler and viewing software.  Glide is the 
virtual screening software. Lig-Prep and Protein Preparation are wizards to prepare 
ligands and proteins for use in Glide respectively.(Friesner et al., 2004; Friesner et al., 
2006; Halgren et al., 2004) 
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Chapter 2:  P53, MDM2, and MDMX 
 
2.1 Cancer 
 Cancer is a genetic disease where cells gain self-sufficiency and ultimately leads 
to tissue destruction and death.  Because of the large array of control systems, the 
evolution of a cancer from genetic abnormality to full-blown neoplasia is a complex one 
that involves specific mutations in both oncogenes and tumor suppressor genes in order 
to undermine normal mechanisms for maintaining controlled cellular development.  As 
these genetic abnormalities accumulate, allow for angiogenesis, evasion of apoptosis, 
self-sufficiency in growth signals, and limitless replication. 
Knudsen’s two hit hypothesis suggests that both copies of a gene must be mutated 
in order cause dysfunction.  A mutation in oncogenes leads to a gain of function 
mutation, a mutation where a cell learns to perform a metabolic function not associated 
with its cell line.  A mutation in tumor suppressor genes leads to a loss of function in a 
critical genetic caretaker that results in incomplete inhibition of pro-tumor process or 
protein.  Oncogenes typically mutate in a way to suppress tumor suppressors and tumor 
suppressors mutations cause a decrease in their activity as promoters of 
apoptosis.(Nordling, 1953) 
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2.2 P53 and Apoptosis 
 Two tumor suppressors that are being intensely studied at this time are the BCL2 
family of proteins and P53(Hollstein, Sidransky, Vogelstein, & Harris, 1991) and its 
regulators MDM2(Momand, Zambetti, Olson, George, & Levine, 1992).  Actually some 
members of the BCL2 family are tumor suppressors (BAX, BAD, BIM) and others are 
proto-oncogenes such as BCL-2, BCL-XL, and MCL-1(Chao et al., 1995).   P53 is the 
chief of the tumor suppressors as it alone initiates apoptosis, however, it is a regulator of 
its function MDM2 and its analog MDMX are proto-oncogenes, as they cause a decrease 
in P53 levels when mutated.(Hollstein et al., 1991) 
 P53 is the gatekeeper of the cell and chiefly responsible for destruction of a cell 
whose ability to survive has been compromised.  Apoptosis, the process by which cells 
initiate death becomes necessary under five conditions:  lack of oxygen, lack of nutrition, 
heat or cold shock, mitotic spindle damage, and genetic instability.  P53 acts as a 
transcription factor for many different apoptosis related proteins.  Each process has its 
own unique mechanism of action that cross at the P53 protein with four outcomes 
possible: senescence, DNA repair, cell cycle arrest, or cell death.(Hollstein et al., 1991) 
P53 consists of three functional domains.  The first of which is the transactivation 
domain, residues 1 – 42, which is responsible for up-regulation of pro-apoptotic genes.  
This is the portion that binds to the regulatory molecule MDM2 at the P53 domain.  The 
P53 binding domain, residues 102 – 292, is where 90% of mutations occur.  This region 
is required for sequence specific binding.  Lastly there is the Oligomerization domain, 
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where P53 forms a tetramer.(Hollstein et al., 1991; Momand et al., 1992; Vassilev et al., 
2004) 
 
!
Figure 7 P53 acts to initiat apoptosis by binding to promoter regions of DNA.  Both 
MDM2 and MDMX act to counter its pro-apoptotic effects and keep it in low 
concentration within the nucleus. 
2.3 MDM2 
 It should also be noted that P53 is responsible for differentiation of certain cell 
lines and especially important in cancers of blood cells.  In cancers such as multiple 
myeloma, higher levels of P53 are linked to worst outcomes and survival.  Apoptosis 
mediated by P53 can be inhibited by MDM2 and MDMX.  These act to remove P53 from 
the nucleus and mediate its destruction.  Because of the importance of P53, cancers in up 
to 50% cases contain some dysregulation of P53.  MDM2 stands for Mouse Double 
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Minute 2 and was discovered along with several DNA binding proteins.  Double Minute 
refers to length of time it took to transverse a chromatography gel.(Lenos & Jochemsen, 
2011) 
P53 binds to MDM2 and MDMX at the P53 binding domain via the trans-
activation domain, a short disordered loop which forms a alpha-helix upon binding.  The 
RING domain of MDM2 binds to a ubiquitin ligase that is responsible for marking P53 
for destruction.  MDM2 can also act to mark other MDM2 proteins and the MDM2 
analog, MDMX, for destruction by the same mechanism.  Some conformational change is 
thought to occur which allows both of these actions to happen, but little is known about 
the mechanics within the disordered residues of MDM2.  This kind of conformational 
change is not uncommon in MDM2/MDMX or P53.(Dunker & Uversky, 2010) 
 Docking studies showed that a indole-like group was necessary to bind to the 
tryptophan binding pocket.  The Leucine binding pocket is very shallow, and therefore 
difficult to model accurately.  The volume of the Leucine pocket is less than one square 
angstrom. 
P53 levels directly lead to increased MDM2 levels.  MDM2 levels are regulated 
by MDM2 – MDM2 complex formation and the ubiquitination of MDM2 when levels are 
high relative to P53 or MDMX levels.  MDMX does not contain ubiquitin ligase and 
interaction with MDM2 does not lead to its destruction.  This increase in MDM2 by an 
increase in P53 is an example of a feedback loop.  This feedback loop is disrupted in 
cancer.  50% of human cancers contain a mutation in P53.  Additionally, 50% of cancers 
contain a mutation of MDM2.  Drugs that can reactivate P53 would be the most direct 
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route to killing cancer cells and restoring homeostasis, the natural functioning of the 
body.(Vassilev et al., 2004) 
 One of the early scientific successes against MDM2 were the Nutlin compounds, 
especially Nutlin-3A.  Nutlin-3A was the first molecule to achieve sub-micromolar 
inhibitory concentrations against MDM2.  This author’s first attempts at inhibitor design 
were centered on screening Nutlin-3A analogs and molecules inspired by the Nutlin 
series of compounds.(Vassilev et al., 2004) 
Table 3 Table of Nutlin Compounds 
!title:!Wang0Nutlin01! !title:!Wang0Nutlin02!
!title:!Wang0Nutlin03B! !title:!Wang0Nutlin03A!
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Figure 8 The four domains of P53 are as follows: P53 Binding Domain, Acidic 
Domain, Zinc Finger, and RING Domain.  The White spaces are represent 
disordered portions of protein. 
 
2.4 MDMX 
 The project was expanded to include MDMX, a close analog and regulator of 
MDM2.  MDM2 and MDMX differ at the RING domain, as MDMX does not have a 
binding domain for ubiquitin ligase, but still retains the ability to export P53 from the 
nucleus to the cytosol.  MDMX has a binding site which is particular problematic, as it 
has a shallower binding pocket when compared to MDM2.(Linke et al., 2008)  Also 
problematic are that  MDMX levels rise along with MDM2 levels and causes loss of 
activity of MDM2 inhibitors as it makes P53 unable for promotion of pro-apoptotic 
factors by exporting it from the nucleus. 
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!
Figure 9 Model of binding site of MDMX showing auxilary binding pocket to left 
and standard grid placement that does not include the auxilary pocket. !
 In addition to small molecule inhibitors cyclic compounds and alpha-helix 
mimetics from the McLaughlin and Del Valle groups were screened against MDM2 and 
MDMX, both containing residues that are hydrophobic. 
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 Later MI-XX series of molecules were discovered.  These compounds were used 
as a basis of a second generation of molecules screened against MDM2.  Moffitt cancer 
!
Figure 10. MDMX overlayed with MDM2.  MDMX with carbon in blue and MDM2 
with carbon in gray. !
produced a series of crystal structures of high affinity optimized peptides based on the 
P53 amphipathic trans-activation alpha helix.  These high-resolution structures were then 
used to find small molecule inhibitors.(Canner et al., 2009) 
The Moffitt series of crystal structures were insightful because one X-ray crystal 
structure contained the peptide PDIQ that appeared to bind to an auxiliary pocket of 
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MDMX that had not been seen before.(Phan et al., 2010)  In addition, the crystal 
structure of MI-63 bound to MDMX contained two bound molecules one bound to the 
auxiliary pocket.(Canner et al., 2009)  Much effort was put into creating a suitable linker 
to take advantage of this auxiliary biding site. 
 
!
Figure 11 Model of crystal structure containing two bound copies of a MI-63 analog. !
 Another interesting feature of MDMX/MDM2 are two residues that appear to 
have much flexibility that separate the usual Phenylalanine, Tryptophan, and Leucine 
pockets from above mentioned auxiliary pocket.  MET – 53 and TYR – 100 on MDMX 
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appear to be able to move enough for a small molecule inhibitor or peptide inhibitor to 
displace them and increase binding area.  One of the first computational experiments 
regarding MDM2 was better understand this interaction. 
 Crystal structures of several peptides were produced by the Moffitt Cancer Center 
as part of MDM2/MDMX program.  Among these structures is one peptide PDIQ (PDB 
ID: 3JZQ showing novel binding to previously unknown site that bound to Leucine side 
chain of PDIQ. 
 
2.5 Methods 
Virtual Screening.  As part of a large screening program to identify inhibitors of 
MDMX, there was a collaboration with Schrödinger Inc., where the NCI plated set, a set 
of plated compounds that are available from NIH was screened against MDMX.  
Schrödinger chose an “open” conformation of MDMX chosen by observing the distance 
between TYR and MET and the proposed auxiliary binding site.  From the Schrödinger 
screening of the NCI plated set, 5 potential inhibitors of MDMX.   
Two of these inhibitors, E12 and A6, are potential binders of the auxiliary binding 
site.  There was intense interest in producing tighter binding analogs of these two.  E12 
was the only one that showed binding to MDMX at 50 um concentration despite 
repeated trials.  As part of this screening regimen, induced fit effects of binding to the 
MDMX binding site were examined in an effort to demonstrate how a small molecule 
might bind to the auxiliary binding site. 
Five molecules were docked via the induced fit protocol, a part of the Schrödinger 
Suite of Programs allowing full flexibility in Met 100 and Tyr 53.  Each was also docked 
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to open and closed confirmations of MDMX via Glide docking using both standard 
precision (SP) and extra precision docking (XP).Table 4 Schrodinger selected compounds 
Table 4 The Five Compounds Chosen By Schrodinger 
The five compounds chosen by Schrodinger that were found by their virtual 
screening that also potentially interact with the auxiliary binding pocket.!
Software.  All software used was part of the Schrödinger Software Suite.(Friesner et al., 
2004; Friesner et al., 2006; Halgren et al., 2004) 
Hardware.  Dell Precision 490 workstation with dual quad-core processors running at 
2.23 GHz and having 9800 GT graphics and 1 TB hard disk. 
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2.6 Conclusion 
 Two generations of analogs were produced based upon virtual screening.  An 
additional two generations of compounds were made based upon the MI-63 compound.  
From screening, we were able to produce an inhibitor with superior MDMX IC50 
concentration from a MI-63 analog compound of 3nm IC50 concentration. (Canner et al., 
2009)  
 It is very possible that a strong enough binder or large enough ligand would have 
enough energy to offset the energy cost of displacing the two side chains.  The Tyrosine 
8.3 A and the Methionine sulphur moved 3.8 A.  The difference in energy between the 
closed and open conformations is about 3 Kcal.  The additional hydrophobic interaction 
is worth a difference of 3 Kcal for the native ligand.  Further study will be needed to fully 
uncover whether this additional binding site is a worthwhile target. 
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Chapter 3:  MDM2/MDMX RING Domain 
 
3.1 Lenalidomide causes dose dependent increase in MDM2 
Lenalidomide is an analog of the notorious Thalidomide that was never approved 
in the United States but was widely used in the United Kingdom and imported into the 
United States through illicitly importing the drug from United Kingdom.  Thalidomide 
was largely hyped at the time as a super drug. It eased the pains of leprosy, as well as 
quelling nausea and vomiting of morning sickness.(Franks, Macpherson, & Figg, 2004; 
Macpherson et al., 2003) 
!
Figure 12 Lenalidomide (left) and Thalidomide (right) !
Lenalidomide is a drug that suppresses multiple myeloma cell differentiation.  It 
directly causes cell to undergo apoptosis within cells by binding to the DDB1, Cullin-4A, 
and ROC1 complex. This complex is activated when ubiquitinates several unknown 
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proteins which through a largely unknown mechanism causes upregulation of fibroblast 
growth factor FGF8.!!Within patients having multiple myeloma, MDM2 levels were seen 
to rise dose dependently.  This is a curious development as the mechanism of action of 
lenalidomide is thought to act via cereblon, a ubiquitin ligase(Ito & Handa, 2012). 
Patients at the Moffitt Cancer Center who undergo treatment for multiple 
myeloma take Lenalidomide to prevent the maturation of Plasma Cells that are cancerous 
in this condition.  Plasma cells mature from B cells and produce immunoglobins which 
provide humoral immunity to pathogens.  Patients were found to have increased levels of 
MDM2 in cellular assays.  This finding is particularly significant because it is known that 
deficiency in P63, a homolog of P53 that also binds to MDM2 causes mice to born 
without limbs and human beings to be born with electrodactyly, lobster claw hand 
syndrome.  The investigation centered around the possibility that lenalidomide and 
thalidomide exerted its effect across ubiquitin ligases, and that in fact P63 may have been 
the cause of limb deformities with or without stabilization of cereblon.(van Straten & 
Butow, 2013) 
 
3.2 MDM2 / MDMX / P53 regulation 
MDMX, a closely related protein to MDM2, has similar activity as MDM2, 
except it does not contain ubiquitin ligase activity.  The RING Domain of MDM2 and 
MDMX lie at their C terminus.  The region acts a regulatory domain for MDM2, 
MDMX, and P53.  MDM2 self regulates through an auto-ubiquitination pathway 
whereby it binds to another molecule of itself and recruits a ubiquitin conjugase enzyme, 
UbcH5b, which tags MDM2 with ubiquitin. This marks it for destruction by the 
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proteosome.  P53 and MDMX is regulated in a similar manner where MDM2 
ubiquitination by MDM2.  MDMX can bind MDM2, P53, and other MDMX molecules 
but cannot mark any of them for destruction.  It can however still remove bound 
molecules from the nucleus, preventing them from promoting transcription.(Linke et al., 
2008) 
MDM2, MDMX, and P53 are subject to post-translational modification as a 
methodology that grants or denies activity; however, it is the MDM2 protein which 
responsible for sequestration and ubiquitination. What enzyme becomes ubiquitinated is 
subject to the concentration of each enzyme.  When MDM2 is in high concentration 
relative to MDMX or P53 it will act upon other MDM2 molecules.  When P53 is in high 
concentration relative to MDM2 or MDMX, the P53 will be ubiquitaninated and 
subsequently destroyed by the proteosome.  When MDMX is in relative abundance 
MDM2 and P53 will be stabilized, as MDMX does not have the ubiquitin ligase 
functionality.(Linke et al., 2008) 
The investigation started with a survey of crystal structures available from the 
pdb.  While there were more than 30 structures for the N-terminal P53 binding domain.  
Only two related structures of the C-terminal RING domain were available (PDB ID: 
2VJE and 2VJF) from the C.L. Day lab at the University of Otago, New Zealand.  
Knowing that the key regulatory portions of MDM2 were that of the RING Domain, and 
tow zinc finger domains, our investigation began with these structures.(Linke et al., 2008) 
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Figure 13 MDM2 domains are shown in color. The two unlabeled central regions 
are zinc finger domains.  The white portions between the colored segments 
represent disorderd portions of the protein. !
!
Figure 14 Regualtion of MDM2 and MDMX are concentration dependent. 
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Figure 15 An Assay showing the MDM2 mediated decrease in P53 levels and the 
effect of lenalidomide. 
 
3.3 Methods 
Because lenalidomide caused an increase in MDM2, our hypothesis was that 
lenalidomide may exert its action via the RING domain ubiquitin conjugase binding 
region.  A similar region exists on Cereblon a well-reported target of Lenalidomide.  
Firstly, Lenalidomide binds to Cereblon an enzyme containing Ubiquitin Conjugase 
Binding domain similar to MDM2.   
Structure Preparation.  There are two X-ray crystallography structures that contain the 
MDM2/MDMX heterodimerization of the RING Domain.  PDB ID: 2VJE and PDB ID: 
2VJF!differ by only be four residues.  These residues lie at the very end of the N-terminus 
and C-terminus of both proteins and so affect the binding site very little.  The 
homodimers were constructed by aligning MDM2 monomer with MDMX monomer and 
vice versa, producing a MDM2 pair and copy as well as MDMX pair and copy. 
 Lenalidomide structures were prepared for docking using Schrödinger’s LigPrep 
2.5 utility.  LigPrep creates a set of 3D computer models that are physiologically 
relevant.  Thus, protonation states that are appropriate for pH’s between 5 and 9 are 
assigned to ionizable groups.  Relevant tautomers are produced and stereoisomers are 
generated if stereochemistry is not known. 
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Molecular Dynamics.  A short ten-nanosecond run was done via Desmond molecular 
dynamics to examine the strength of the heterodimer and the homodimers. 
Virtual Screening.  SITEMAP predicted two possible binding sites on MDM2 and one 
on MDMX.  Both contained a possible binding site near dimer interface where a alpha-
helix resides.  MDM2 additionally contained a possible binding site near the zinc finger 
domain which is also the site that binds to ubiqutin ligase. 
Taking the consideration of the SITEMAP output but also wanting to be 
thorough, grid files were calculated using Glide molecular docking for every part of 
dimer and each of the monomers.  Glide has a built in limitations regarding the number of 
grid points that despite a long effort was met with no success.  Higher grid point density 
led to better docking pose reproduction with x-ray crystal.  So, instead six grids were 
made for the dimer and two grids for each of the monomers of MDM2 and MDMX.  
Each grid contained large areas of overlap in order to prevent some areas from not being 
docked to.  This methodology was intended to function as a chemical probe might. 
 Computational docking of Lenalidomide was performed against the MDM2 and 
MDMX’s RING Domain as receptors.  S and R enantiomers of Lenalidomide were 
docked separately.  The X-Ray Crystal Structure (PDBID:  2VJF) for the MDM2 and 
MDMX’s RING DOMAIN was prepared using Schrödinger’s Protein Preparation 
Wizard.  Docking was performed on monomeric MDM2 and MDM2 as well as the 
heterodimer of the two RING domains.  Since no binding site had previously been 
described,  Shrödinger’s SiteMap program was used to find potential binding 
sites.(Friesner et al., 2004; Friesner et al., 2006; Halgren et al., 2004)
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!
Figure 16 MDMX Heterodimer.  MDMX(green) is on the left and MDM2(white) on 
right. 
 
3.4 Results 
 Output from SiteMap indicated a potential binding site may exist in a shallow 
hydrophobic pocket between the E2 conjugase binding and dimerization regions.  
Docking was performed using Schrödinger’s Standard Precision (SP) GLIDE software2.  
The best docking poses were chosen by highest binding affinity / lowest energy. 
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Table 5 Summary of Lenalidomide Screening 
Ligand Docking Score 
Lenalidomide (S) -5.2 KCal/mole 
Lenalidomide (R) -5.0 KCal/mole 
 
 Linke et al published results along with crystal structure that suggest that 
hydrophobic interactions were critical to E2 Conjugase recruitment.  When I440, L468 
and P476 is mutated, recruitment is abolished and MDM2 mediated degradation is not 
observed.  The Docking pose of Lenalidomide is seen (Figure 2) binding to the 
hydrophobic pocket just beyond the E2 conjugase binding region suggested by Linke et 
al.(Linke et al., 2008)  In all cases, the S enatiomer has a lower docking score than the R 
enantiomer.  However, the difference in docking score is not greater than the 2.0 
KCal/mole absolute error.  The S enantiomer forms a hydrogen bond within the proposed 
binding pocket while the R enatiomer forms a hydrogen bond to an area not likely 
exposed in full length MDM2.  It is evident that the R enantiomer binds with a lower 
affinity than docking would suggest. 
 Currently there is an effort to quantify binding biophysically, but that work is 
ongoing.  Many questions remain about the whether lenalidomide binds to MDM protein 
monomers or to the dimer.  The docking would suggest that the dimer is necessary.  
Expressing the MDMX/MDM2 dimer has not been done yet, but should be done in the 
near future. 
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Figure 17 Figure showing the binding of Lenalidomide to MDM2/MDMX 
heterodimer. 
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Figure 18 In this figure lenalidomide is docked to the binding site found by SiteMap.  
The S enantiomer (right) interacts with the ubiquitin ligase site and the R enatiomer 
(left) does not bind to the pocket. !
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Chapter 4:  BCL-2 Family 
 
4.1 BCL-2 Family 
 The BCL-2 family of proteins contains many oncogenes and tumor 
suppressors that act together to regulate apoptosis, especially apoptosis initiated by c-
myc.  Although c-myc is a proto-oncogene it actually is an inducer of apoptosis; it 
however, also causes telomerase activation.  Through inhibition of BCL-2 family proteins 
apoptosis is inhibited while the telomerase activity is preserved.  This is a pathway by 
which cells become immortalized. The BH3 domain members of the BCL-2 family are 
pro-apoptotic tumor suppressors that are regulated by binding to a long hydrophobic cleft 
in pro-survival MCL-1, BCL-XL, and BCL2 proper.  In similar fashion to P53, pro-
apoptotic factors of the BCL-2 family can be sequestered by BCL-XL and MCL-1, anti-
apoptotic BCL-2 family members and potential proto-oncogenes.  The pro-apoptotic 
factors Bim, Bid, Bad, Bik, Puma, and Noxa regulate cell permeability and control the 
release of cytochrome C and other death factors.  BCL-XL and MCL-1 regulate these 
other members of the BCL-2 family by binding to amphipathic helix at the C-terminus.  
Disrupting this regulation is of great importance to inducing apoptosis in transformed 
tumor cells.(Reed, Zha, Aime-Sempe, Takayama, & Wang, 1996) 
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Figure 19 This figure illustrates the 4 hydrophobic binding pockets of MCL-1.  
These 4 hydrophobic residues of a region of BIM which binds to MCL-1 form the 
basis of inhibition design. 
The drug discovery focus is this regard are the design of small molecule inhibitors 
which mimic the BH3 domain and disrupt this domain from binding to MCL-1, BCL-XL, 
and BCL2.  Generally the search has centered around producing a pan-inhibitor of all 
three, however the most well known BH3 domain inhibitor is the Abbott compound 
ABT-737 which binds with high specificity to BCL-XL.(Kline et al., 2007)  
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Figure 20 MCL-1's binding is considerably more shallow than BCL-XL. !
 Binding to BH3 domain is governed by binding to a series of three to four 
adjacent hydrophobic pockets, which correspond to two isoleucines, a leucine, and 
phenylalanine  on the BH3 domain.  
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Figure 21 BCL-XL and MCL-1 are responsible for BAX and BAK regulation. 
 
4.2 Methods 
To support the in vitro screening of efforts of Del Valle and Manetsch lab, several 
compounds were docked to MCL-1.   The Manetsch lab in particular was interested in 
screening many compounds via a click chemistry methodology, which involved the 
reaction between a sulfoazide and a amino-acetal group.  This reaction occurs only if 
both fragments bind the site of the reaction in a geometrically favorable position, which 
leads to reaction completion. This is known as Kinetic TGS.(Namelikonda & Manetsch, 
2012) 
Click chemistry is a technique first described by Nobel Laureate Dr. K. Barry 
Sharpless of Scripps Research Institue in 2001.  It involves using simple reactions with 
common conditions in either water or solvent.  TGS is an expanded idea of Click 
Chemistry in that using these simple reactions to perform combinatorial chemistry.  In 
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this case the reaction occurs between an azide and a thio-acid, Figure 20.(Namelikonda & 
Manetsch, 2012) 
 
!
Figure 22 General scheme for TGS synthesis !
Combinatorial Screening.  All combination of fragments produced by Manetsch lab were 
screened using Schrödinger’s Glide SP.  We determined early on by comparing hits to 
IC50 values that Glide SP was the scoring function which best correlated with the 
inhibitory concentration for this particular reaction. 
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Figure 23 A) Thermal guided synthesis B) Kinectic guided synthesis(Namelikonda 
& Manetsch, 2012) 
  
Methods. Schrödinger Glide1, 2 (version 5.0) dockings(Friesner et al., 2004; Friesner et 
al., 2006; Halgren et al., 2004) were performed at standard precision for TGS compound 
structures containing one each of thiol acid (TA) and sulfonamide azide (SZ) fragments.  
PDB 2NL9(Czabotar et al., 2007), a 1.55 Å resolution structure of Mcl-1 complexed with 
the Bim BH3 peptide, was downloaded from the Protein Data Bank (PDB)(Berman et al., 
2000; Bernstein et al., 1977) and prepared into grid files for docking.  Correlation of 
docking scores and IC50 values yielded R2 = 0.44, an adequate value for use of this 
model.  The top 2 kcal/mol docking modes consisted of 45 of 58 (77%) of the 
compounds.  Fragment and cluster analysis of the top 2 kcal/mol ranked docking poses 
identified SZ31 to be most frequent among the SZ fragments while structures containing 
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SZ15 were next in number to provide a similar binding mode as the SZ31 cluster of 
docking modes.  These findings corresponded well with IC50 data where all compounds 
with the SZ31 fragments exhibited a range of 3.5 – 16.4 µM. 
Overlaying the SZ31 fragment-containing structures in the top 2 kcal/mol docking 
modes revealed one cluster with 1) an acyl-sulfonamide hydrogen bonding with Arg263, 
a conserved residue of Mcl-1 known to hydrogen bond with Asp67 of the Bim BH3 
peptide,3 2) the thio-phenyl and benzo-dioxalane groups of the SZ31 fragment occupying 
the P1 and P3 pockets, respectively, and 3) the TA fragments occupying the binding 
region between Arg263 and the P4 pocket. 
Specificity. Mcl-1 over Bcl-xL. Similar docking and analysis of the TGS compounds 
were performed on PDB 3FDL(Merino et al., 2009), a 1.78 Å resolution structure of Bcl-
xL.  Fragment analysis of the top 2 kcal/mol identified a high-number clustering of TA11 
fragment compounds not found in the Mcl-1 docking poses.  The SZ15 docking modes of 
the top 2 kcal/mol structures also provided a cluster of poses; however, since similar data 
also appeared in the Mcl-1 dockings, the TA11 fragment cluster suggests a flatter 
substituent for specificity towards the shallower P4 pocket of Mcl-1.  Analysis of SZ31 
molecule docking modes between Mcl-1 and Bcl-xL revealed that specificity can be 
attained for Mcl-1 by having a flat TA fragment coupled to SZ31 by increasing ligand 
strain energy due to the deeper P2, P4 pockets of Bcl-xL. 
The Mcl-1 top 2 kcal/mol cluster led to further investigation of SZ31TA2 using 
CombiGlide to first explore potential linkers then suitable R-groups for extension of the 
SZ31 fragment through the h1 pocket to secure a hydrogen bonds with Ser245 and/or 
Arg248.  Further, cross-docking studies data recognized TA11 as a potential structure to 
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optimize for specificity of Mcl-1 over Bcl-xL. Recommended to the Manetsch Lab 1) the 
synthesis of a para-sulfonamide linker to the thio-phenyl group of SZ31 together with an 
para-ethyl-benzoic acid and 2) the analog library development of flat aromatic system for 
the TA fragments. 
 
Table 6 Top scoring TGS compounds. 
TGS Compound Specificity Index 
(glide score / glide score) 
SZ31TA02 60.6 
SZ31TA08 15.6 
Sk-2-172 15.2 
SZ31TA03 8.62 
SZ31TA07 5.66 
SZ31TA06 3.29 !
!
Figure 24 Correlation between SP Docking and IC50 for TGS compunds 
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We speculated that Glide XP that includes much steeper penalties for solvent 
exposure was over penalizing hydrophobic atom’s exposure to water.  Most protein-
protein interaction binding sites have large shallow pockets where high penalties for 
solvent exposure are probably not appropriate. 
 Taking the two best compounds at the time, SZ15TA03 and SZ31TA02, we 
employed combiglide enumeration with the Schrödinger fragment library in order to 
extend each compound with a hydrophilic substituent that would increase activity with 
Arginine 248 of MCL-1 and decrease solvent exposure in the Phenylalanine pocket. 
!
Figure 25 ARG 248 looked to be a site for potential extension of SZ31 
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Software. All software used was part of the Schrödinger Software Suite. 
Hardware.  Dell Precision 490 Workstation with dual quad-core processors running at 
2.23 GHz and having 9800 gt graphics and 1 TB hard disk. 
Extension toward Arginine 248.  Several new libraries were created to based upon the 
best compounds, SZ31TA02 and SZ15TA03 with the intention of increasing the binding 
to MCL-1 and possibly increasing specificity.  These new libraries were screened against 
2NL9 using GLIDE.(Friesner et al., 2004; Friesner et al., 2006; Halgren et al., 2004) !
!
Figure 26 This site is highly solvent exposed 
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Figure 27 Our final molcule bound to MCL-1.  This compound docked at -11.48 
Kcal/mol. 
 
4.3 Conclusion and Future Direction 
Although our modifications did lead to a decrease in IC50 to 11 µM it was six 
times more specific for MCL-1 than previous compounds.  Despite having a higher 
overall docking score, the ligand efficiency decreased.  This demonstrates a fundamental 
problem of scoring functions in that higher molecular weight compounds tend to have 
higher docking score because more ligand atoms contribute to the calculation.  Our 
speculation is that by focusing on ligand efficiency in the future this problem can be 
avoided. 
The current focus of this project is on predicting the occurrence of click reactions 
on the BCL-XL surface.  The current methodology is to dock molecules into each of the 
four pockets and then using scripts to calculate the distance from reactive sulfur to 
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nitrogen.  By producing a list of structures ranked by their distance, we hypothesize the 
lower distances will correlate with probability for reactions occurring.  One issue that has 
come to light is the relative non-specificity of the largely hydrophobic fragments.  Our 
findings will be published in a paper in the near future. 
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Chapter 5:  Virtual Screening against Deoxycytidine Kinase 
 
5.1 Introduction 
One of the most important enzymes for cancer drug discovery is the enzyme 
Deoxycytidine Kinase (DCK).  DCK's function is to catalyze the phosphorylation of 
nucleosides.  Once nucleosides have been phosporylated they become 
monophosphorylated nucleotides.  The nucleotides will then be phosphorylated a further 
two times to form triphosphorylated nucleotides.  Finally triphosphate nucleotides are 
used as energy currency in the cell and also the building blocks of DNA and RNA.  DCK 
phoshorylates deoxyribonucleosides specifically for incorporation into DNA.  Because 
DCK functions to build genetic building blocks, it is of interest in both producing 
medicines for cancer and antimicrobial agents.  DCK is therefore said to be a 
promiscuous enzyme because it phosphorylates deoxycytidine along with several other 
deoxynucleosides. The ability of DCK to phosphorylate a wide range of both purine and 
pyrimidine nucleosides makes it a good target.(Usova, Maltseva, Foldesi, 
Chattopadhayaya, & Eriksson, 2004) 
Table 7 shows many of the prodrugs that already exist that use DCK as activator 
of their functionality.  These drugs are known as anti-metabolites including acyclovir and 
ganciclovir.  These anti-metabolites become incorporated into the DNA of the host 
organism but also deplete ATP molecules because DCK phosporylates the fraudulent 
bases.(Rejiba, Bigand, Parmentier, & Hajri, 2009; Usova et al., 2004) 
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Table 7 List of Deoxycitidine Kinase Activated Compounds 
Citidine Antimetabolites Characteristics Category  Treats 
Gemcitabine(Rejiba et al., 
2009) 
Hydrogen atoms on 2' C 
of deoxycytidine are 
replaced by Fluorine. 
Chemotherapy breast cancer, 
ovarian cancer, 
non-small cell 
lung cancer, and 
pancreatic cancer 
 
Cytarabine(Wang et al., 
1997) 
a.k.a cytosine arabinoside; 
kills cancer by interfering 
with DNA synthesis 
Chemotherapy acute myeloid 
leukemia and non-
Hodgkin 
lymphoma 
Clofarabine(Zhang, Secrist, 
& Ealick, 2006) 
kills leukemia cells in 
blood 
Chemotherapy relapsed or 
refractory acute 
lymphoblastic 
leukemia 
Acyclovir(Santos et al., 
2009) 
acycloguanosine Antiviral Treates Herpes 
Simplex and 
Herpes Zoster 
Ganciclovir(Hible, 
Daalova, Gilles, & Cherfils, 
2006) 
9-(1,3-dihydroxy-2-
propoxymethyl)guanine 
Antiviral Treats 
cytomegalovirus 
Zalcitabine(Horwitz, Chua, 
Noel, & Donatti, 1967) 
dideoxycytidine Antiviral  HIV 
 
DCK is found to have increased expression in a few important cell lines.  It is 
found increased frequency in cells of the thymus and those of lymphocites, white blood 
cells.  This makes drugs activated by DCK important for drug discovery against Acute 
Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL).  In Herpes 
Simplex Virus (HSV), Deoxycytidine Kinase is induced in order to speed the replication 
of new viral DNA.(van der Wilt et al., 2003) 
There are quite a lot of anti-metabolites as marketed drugs whose function is 
governed by DCK.  The list includes drugs that act on herpes viruses and lymphocytic 
cancers.  Resistance to DCK occurs through two distinct mechanism.  One mechanism 
involves the alternative splicing of DCK.  The other is through mutation in the genes that 
 61 
control the HERT transporter genes.  The HERT transporters are responsible for 
transporting Nucleosides into the nucleus. 
 
5.2 Methods 
Software.  All software used was part of the Schrödinger Software Suite. 
Hardware.  Dell Precision 490 workstation with dual quad-core processors running at 
2.23 GHz and having 9800 GT graphics and 1 TB hard disk. 
Through our collaboration with the Southern Research Institute and the labs of 
Dr. Steven Ealick and Dr. John Secrist, III we received a set of potential DCK ligands for 
screening.  These were all potential prodrugs that could be activated by DCK. 
PDB ID:  2A7Q is  a DCK structure solved by the Ealick group using X-ray diffraction 
methods and was used as the sole target of our virtual screening. 
Because anti-metabolites are not inhibitors but active substrates of DCK, the 
overall magnitude of docking score can not be the sole deciding factor in choosing a set 
of ligands for screening. Careful consideration of the number of hydrogen atoms and 
ligand geometry must be considered as well.  With so many market drugs that work 
through activation of DCK, a statistical analysis can be done comparing those scores with 
our set of potential anti-metabolites. 
From the initial screening several molecules showed strong activity.  Oddly some 
molecules with very similar structure show no potential activity.  In this case our 
screening focus was changed to that of an investigation of interactions with DCK and the 
formulation of a hypothesis explaining the differences in interaction. 
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5.3 Results 
Table 8 Activities and Docking scores for the best compounds. 
 
 
In Figure 1 we have the best compounds from the set compounds from the Ealick group.  
Despite several of the molecules sharing vary similar structures (Figure 2) the activities 
vary widely. 
Activities seem to decrease with polarity of the sugar group.  Where as the 
nucleoside base group seems to make less difference in activity.  When looking at the 
overall docking score, activities are relatively the same.  Looking at docking pose 
however reveals a greater number of hydrogen bonds with the more polar sugar group in 
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less active compounds.  The less active compounds contain an additional fluoromethyl as 
in figure 2 or hydroxymethyl at the first postion of the sugar portion of the nucleoside. 
 
 
Figure 28 These two molecules differ only in the placement of one Fluorine Atom.  
Yet one is active (31 nm) and one is inactive (800 µm).  The docking scores are 
within 1.2 Kcal/mole of one another. 
 
5.4 Conclusion 
Through screening ligands against the Ealick Crystal Structure (PDB ID: 2A7Q) 
we found that overall score was not as important as our hypothesis.  From the list actives 
and related molecules we found that in all cases the inactive analog contained additional 
hydrogen bonding which led to increase in binding and a possible prolonged interaction 
within the binding site.  This additional hydrogen bonding we proposed would lead to 
decrease in the dissociation constant leading to an overall decrease in reaction rate.  An 
initial set of compounds was sent to us by the Secrist group for evaluation against DCK.  
The purpose of this evaluation was to design an inhibitor across several cancer cell lines.  
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This initial set of compounds was then tested and another set of compounds were then 
sent to us.  From these two sets compounds several possible actives were found.  Several 
very similar compounds to the active compounds were also tested but found to be 
inactive in the modeling studies.  It then became the task of this lab to discern the reason 
for the inactivity. We found that the inactivity was the result of tighter binding than it's 
counterpart usually differing by a hydrogen bond.  We propose that the additional 
hydrogen binding leads an decreased reaction rate or in Michaelis Menten kinetics, a 
decrease in Km. 
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A. MDM2 Inhibitors and Glide Scores 
 
Table A-1 List of Docking Scores of Known Inhibitors of MDM2 
 
title: stoll-chalcone-b1 
glide gscore: -6.502 
 
title: Dudkina-Benzodiazepine-29 
glide gscore: -6.294 
 
title: Stoll-chalcone-c 
glide gscore: -6.262 
 
title: Stoll-Chalcone-a 
glide gscore: -6.144 
 
title: Hardcastle-Isoindolinone-2y 
glide gscore: -6.003 
 
title: Parks-Benzodiazepine-10 
glide gscore: -5.909 
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title: Parks-Benzodiazpine-42 
glide gscore: -5.907 
 
title: Dudkina-Benzodiazepine-31 
glide gscore: -5.899 
 
title: Hardcastle-Isoindolinone-2v 
glide gscore: -5.782 
 
title: Walton-PFT-A 
glide gscore: -5.759 
 
title: Wang-Nutlin-3B 
glide gscore: -5.731 
 
title: Parks-Benzodiazepine-40 
glide gscore: -5.714 
 
title: Walton-PFT-B 
glide gscore: -5.702 
 
title: Parks-Benzodiazepine-29 
glide gscore: -5.671 
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title: Dudkina-Benzodiazepine-30 
glide gscore: -5.65 
 
title: Walton-PFT-B 
glide gscore: -5.616 
 
title: Galatin-Sulfonamide 
glide gscore: -5.6 
 
title: Parks-Benzodiazepine-28 
glide gscore: -5.599 
 
title: Parks-Benzodiazepine-18 
glide gscore: -5.579 
 
title: Parks-Benzodiazepine-22 
glide gscore: -5.563 
 
title: Parks-Benzodiazepine-21 
glide gscore: -5.558 
 
title: Parks-Benzodiazepine-27 
glide gscore: -5.531 
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title: Parks-Benzodiazepine-20 
glide gscore: -5.515 
 
title: Parks-Benzodiazepine-14 
glide gscore: -5.485 
 
title: Parks-Benzodiazepine-35 
glide gscore: -5.481 
 
title: Parks-Benzodiazepine-17 
glide gscore: -5.457 
 
title: Parks-Benzodiazepine-15 
glide gscore: -5.384 
 
title: Parks-benzodiazepine-5 
glide gscore: -5.376 
 
title: Parks-Benzodiazepine-24 
glide gscore: -5.355 
 
title: Parks-Benzodiazepine-30 
glide gscore: -5.299 
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title: Parks-Benzodiazepine-23 
glide gscore: -5.29 
 
title: Parks-Benzodiazepine-25 
glide gscore: -5.261 
 
title: Dudkina-Benzodiazepine-27 
glide gscore: -5.261 
 
title: Parks-Benzodiazepine-7 
glide gscore: -5.244 
 
title: Parks-Benzodiazepine-41 
glide gscore: -5.222 
 
title: Stoll-chalcone-b 
glide gscore: -5.195 
 
title: Hardcastle-Isoindolinone-2z 
glide gscore: -5.236 
 
title: Dudkina-Benzodiazepine-28 
glide gscore: -5.162 
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title: Parks-benzodiazepine-4 
glide gscore: -5.15 
 
title: Parks-Benzodiazepine-11 
glide gscore: -4.922 
 
title: Hardcastle-Isoindolinone-2z 
glide gscore: -4.938 
 
title: Wang-Nutlin-3A 
glide gscore: -4.785 
 
title: Parks-Benzodiazepine-3 
glide gscore: -4.681 
 
title: Parks-Benzodiazepine-31 
glide gscore: -4.675 
 
title: Hardcastle_isoindolinone-2x 
glide gscore: -4.584 
 
title: Parks-Benzodiazepine-19 
glide gscore: -4.578 
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title: Parks-Benzodiazepine-37 
glide gscore: -4.573 
 
title: Parks-Benzodiazepine-32 
glide gscore: -4.552 
 
title: Parks-Benzodiazepine-12 
glide gscore: -4.475 
 
title: Parks-Benzodiazepine-13 
glide gscore: -4.462 
 
title: Parks-Benzodiazepine-38 
glide gscore: -4.362 
 
title: Parks-Benzodiazepine-34 
glide gscore: -4.353 
 
title: Parks-Benzodiazepine-43 
glide gscore: -4.293 
 
title: Parks-Benzodiazepine-40 
glide gscore: -4.235 
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title: Parks-Benzodiazepine-6 
glide gscore: -4.229 
 
title: Parks-Benzodiazepine-41 
glide gscore: -4.222 
 
title: Parks-Benzodiazepine-26 
glide gscore: -4.184 
 
title: Parks-Benzodiazepine-1 
glide gscore: -4.174 
 
title: Parks-Benzodiazepine-33 
glide gscore: -3.863 
 
title: Dudkina-Benzodiazepine-32 
glide gscore: -5.047 
 
title: Hardcastle-Isoindolinone-2w 
glide gscore: -3.76 
 
title: Hardcastle-Isoindolinone-2z 
glide gscore: -4.932 
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title: Hardcastle-Isoindolinone-2z 
glide gscore: -4.503 
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B. Ramachandran Plots From Building RING Domain Homodimers 
 
Figure A-1 Ramachandran plot for the homodimer built only by aligning MDMX 
monomers. 
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Figure A-2 Ramachandron plot based on MDMX homodimer after 10 ns MD run. 
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Figure A-3 The Ramachandron plot for a MDM2 RING Domain homodimer built 
only by aligning molecules. 
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Figure A-4 The Ramachandran plot for MDM2 after a 10 ns molecular dynamics 
run. final_mdm2_01.ps
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C. Plots of NCID2 Screening Against MDM2 RING Domain 
 
 
 
Figure A-5 Area C1 Docking into Ring Domain of PDB ID: 2VJF. 
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Figure A-6 Area C2 Docking into Ring Domain of PDB ID: 2VJF 
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Figure A-7 Area D1 Docking into Ring Domain of PDB ID: 2VJF 
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Figure A-8 Area D2 Docking into Ring Domain of PDB ID: 2VJF 
0"100"200"
300"400"500"
600"700"800"
900" 2VJF%D2%Docking%Scores%
NCID"1"Count"
0"100"200"
300"400"500"
600"700"800"
900" 2VJF%D2%NCID%1%Ef7iciency%
NCID"1"Count"
 84 
 
 
 
Figure A-9 Area CD1 Docking into Ring Domain of PDB ID: 2VJF 
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Figure A-10 Area CD1 Docking into Ring Domain of PDB ID: 2VJF 
0"100"200"
300"400"500"
600"700"800"
2VJF%CD2%Docking%Score%
NCID"1"Count"
0"100"200"
300"400"500"
600"700"800"
900" 2VJF%CD2%NCID%1%Ef7iciency%
NCID"1"Count"
 86 
 
 
 
Figure A-11 Area CD3 Docking into Ring Domain of PDB ID: 2VJF 
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Figure A-12 Area CD4 Docking into Ring Domain of PDB ID: 2VJF 
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Figure A-13 Area CD5 Docking into Ring Domain of PDB ID: 2VJF 
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Figure A-14 Area CD6 Docking into Ring Domain of PDB ID: 2VJF 
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Mcl-1, an anti-apoptotic member of the Bcl-2 protein family, is overexpressed in a broad range of human 
cancers and plays a critical role in conferring resistance to chemotherapy. In the course of screening a 
natural product-like library of sesquiterpenoid analogs, we identified substituted hexahydronaphtha- 
lenes that showed activity against the Mcl-1/BimBH3 interaction in vitro. Here, we describe the synthesis 
of a small library of analogs and their biological evaluation. The most potent inhibitor in the series (19) 
exhibits an IC50  of 8.3 lM by ELISA and disrupts the interaction between endogenously expressed Mcl-1 
and Bim in cultured MDA-MB-468 breast cancer cells. 
© 2012 Elsevier Ltd. All rights reserved. 
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!
Bcl-2 family proteins regulate apoptosis through their influence 
on mitochondrial outer membrane (MOM) permeability and the O O 3 
release of cell death factors such as cytochrome c in response to 
cellular stress.1–3 Bax and Bak are pro-apoptotic multidomain 
(BH1–BH4) family members necessary for apoptosis and are di- 
rectly involved in binding to the MOM.4 Other pro-apoptotic Bcl- 
2 proteins such as Bim, Bid, Bad, Bik, Puma, and Noxa contain only 
a single BH3 domain and indirectly modulate MOM permeability 
upstream of Bax and Bak.5 The anti-apoptotic family members Bcl-
2, Bcl-xL, Bcl-w, Mcl-1, and Bfl-1 exert their influence by hete- 
rodimerizing  with  these  pro-apoptotic  substrates.6–8 
Mcl-1 is over-expressed in greater than 50% of hepatocellular 
carcinomas,9  pancreatic  adenocarcinomas,10  cervical  cancers,11 
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Figure 1. Structure of hexahydronaphthalene 1 and analogs. 
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OTMS 
non-Hodgkin’s lymphomas,12 and non-small cell lung cancers.13 
Mcl-1 is known to compensate for the loss of Bcl-2 or Bcl-xL activ- 
ity induced by selective antagonists14,15 and is especially well sui- 
ted to provide protection from apoptosis due to its relatively short 
half-life (between 0.5 and 3 h).16 Mcl-1 is thus a critical survival 
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factor in a variety of human tumors and has emerged as a promis- 
ing target for small molecule inhibitors. 
In our search for new antagonists of anti-apoptotic Bcl-2 pro- 
teins, we screened a small in-house library of natural product-like 
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Table 1 
Inhibition of the GST-Mcl-1/BimBH3 interaction by ELISA at 25 lM (mean given with standard deviation, n = 3) 
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Table 1 (continued) 
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scaffolds for activity against the Mcl-1/BimBH3 interaction. This 
resulted in the identification of hexahydronaphthalene 1 (Fig. 1) 
as hit compound for further investigation. Here, we describe the 
synthesis of analogs of 1 and their biological evaluation as novel 
Mcl-1 antagonists. 
The hexahydronaphthalene core structure was prepared via 
Diels-Alder reaction between dihydrobezaldehyde derivative 317 
and (E)-trimethyl((3-methylbuta-1,3-dien-1-yl)oxy)silane under 
thermal conditions (Scheme 1).18 Treatment of the intermediate 
cycloaddition adduct with TBAF in THF promoted silyl ether cleav- 
age and concomitant alkene migration to give core structure 4 as a 
single diastereomer. Extensive 2D NMR experiments established 
the structural connectivity of the product while relative stereo- 
chemistry was confirmed by X-ray diffraction of reduced derivative 
9.18 Presumably, treatment of the intermediate Diels-Alder adduct 
with TBAF promotes retro-aldol ring opening and equilibration to 
the more stable a-OH isomer. While the precise mechanism of 
the concomitant alkene migration is unknown, this process seems 
to occur during the retro-aldol reaction and ultimately gives rise to 
a lower energy didehydrodecalin. The relative stereochemistry of 
the hexahydronaphthalene scaffold was confirmed by X-ray dif- 
fraction of diol derivative 5. 
Elaboration of 4 into the desired compounds was achieved 
through silylation of the secondary alcohol followed by aldehyde 
reduction and conversion to the methoxymethyl ether  7 
(Scheme 2). To assess the impact of the amide substituent of 1 
on biological activity, we prepared truncated analogue 8 via silyl 
ether cleavage and reaction of the resulting alcohol with cyclo- 
hexylisocyanate. Hydrolysis of 7 followed by dialkylation afforded 
analogs 10 and 11. Condensation of 9 with various amines and sub- 
sequent carbamoylation gave  a  series of diversely  substituted 
hexahydronaphthalenes for biological evaluation. 
All newly synthesized compounds were tested for their ability 
to block the interaction between GST-Mcl-1 and the BimBH3 do- 
main in an ELISA assay19,20 at a single concentration (25 lM). A 
peptide corresponding to the BimBH3 helix was used as a reference 
inhibitor and average percent inhibition was calculated from three 
separate experiments. As shown in Table 1, initial lead compound 1 
exhibited >50% inhibition of Mcl-1 at 25 lM. Truncations at either 
end of the hexahydronaphthalene core as in 5, 9, and 12 resulted in 
diminished activity, as did the introduction of a more polar mor- 
pholine group in place of the isobutenyl amide as in 22. Various 
hydrophobic substitutions were well tolerated, with the exception 
of the smaller cyclopentyl and isopropyl carbamates in 17 and 18. 
The 3-chlorophenyl carbamate derivative (19) exhibited slightly 
enhanced activity. Compound 10, which is readily accessible from 
the core scaffold via dialkylation, also showed significant inhibition 
at 25 lM. 
We then selected the three most active compounds from single 
dose testing for determination of IC50 values. Figure 2 depicts the 
ELISA dose response curves for compounds 10, 19, and 23 over a 
range of concentrations between 0.1 and 100 lM. Each compound 
exhibited dose-dependant inhibition of Mcl-1 in the micromolar 
range. The most potent compound, 19, showed an IC50 of 8.3 lM 
in vitro. 
We next determined whether the most potent inhibitor in vitro 
(19) is able to enter human cancer cells, reach its target and disrupt 
the Mcl-1/Bim interaction. To this end, we treated MDA-MB-468 
human breast cancer cells that ectopically express Bcl-xL and 
Bim with either vehicle V (0.1% DMSO) or 19 at 25 or 50 lM, lysed 
the cells, immunoprecipitated Mcl-1 from the lysates and immu- 
noblotted with Bim as described by us previously.21 As a positive 
control we used BH3M6, a substituted terphenyl derivative that 
has previously been shown to disrupt the interaction of various 
anti-apoptotic Bcl-2 family proteins with Bim in whole cells.21 
TPC, an unsubstituted analog of BH3M6 with no appreciable 
in vitro activity was also included as a negative control. Figure 3 
shows that in vehicle-treated MDA-MB-468 cells Bim co-immuno- 
precipitated with Mcl-1. Similarly, cells treated with negative 
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Figure 2. ELISA Mcl-1/BimBH3 dose–response curves for 10, 19, and 23 (95% 
confidence intervals in parentheses). 
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result in greater cytotoxicity. Poor solubility in culture medium be- 
yond 100 lM precluded an accurate determination of GI50 values. 
To gain structural insight into the possible binding interaction 
between 19 and Mcl-1, we performed computational docking 
experiments using the GLIDE protocol. Since 19 was produced as 
a racemic mixture, we docked both enantiomers to the X-ray crys- 
tal structure of human Mcl-1 (derived from PDB code 2NL9).22 
Figure 4 depicts the top scoring docking poses for each antipode, 
both of which bind to the hydrophobic cleft occupied by the BH3 
helical domains of pro-apoptotic partners. Notably, the two large 
hydrophobic groups of the 1R,4aS,6R,8aS enantiomer (isobutenyl 
and 3-chlorophenyl) bind to the sites on Mcl-1 that normally 
accommodate the Leu62 (i+4) and Phe69 (i+11) side chains in 
human Bim (Fig. 4A). While the 3-chlorophenyl substituent in 
the 1S,4aR,6S,8aR enantiomer also appears to mimic the Phe69 res- 
50    100 
!
!
0 
96.9 !
61.9 55.
7 
!
70.6 !
46.4 
idue, the isobutenyl substituent resides well outside of the Leu62 
pocket (Fig. 4B). In both docked structures, the methoxymethyl ether 
substitutent of 19 makes extensive stabilizing contacts with Asn260 
V 25      50      25      50      25      50 
TPC BH3M6 19 
(µM) and Arg263 in Mcl-1. Furthermore, this functional group overlays 
well with the carboxy side chain of Asp67 (i+9) in human Bim. 
In summary, we have described the synthesis and preliminary 
Figure 3. Co-immunoprecipitation of Mcl-1 (with Bim) from MDA-MB-468 cells. 
(A) Samples compared in the same gel for each protein and (B) densitometric 
analysis of inhibition. 
!
!
control TPC also show complex formation between Mcl-1 and Bim. 
In contrast, 19 inhibited the interaction between Mcl-1 and Bim at 
both 25 and 50 lM. Compound 19 had similar potency to BH3M6 
at both concentrations. 
Compound 19 also exhibited approximately 80% growth inhibi- 
tion toward MDA-MB-468 cells above 100 lM by MTT assay (see 
Supplementary data). However, increased concentrations did not 
!
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Figure 4. Top-scoring poses for (A) (1R,4aS,6R,8aS)-19 and (B) (1S,4aR,6S,8aR)-19 
docked to human Mcl-1 (PDB code 2NL9) using GLIDE. 
SAR for a series of hexahydronapthalenes that disrupt the Mcl-1/ 
BimBH3 interaction in vitro. The most potent inhibitor in the series 
(19) exhibits an IC50  of 8.3 lM by ELISA. Compound 19 also dis- 
rupts the interaction between endogenously expressed Mcl-1 and 
Bim in intact MDA-MB-468 breast cancer cells. Computational 
docking suggests that 19 interacts with the BH3-binding hydro- 
phobic cleft in human Mcl-1. Efforts toward the synthesis of enan- 
tiopure 19 and other analogs for evaluation against a wider panel 
of anti-apoptotic Bcl-2 family proteins are currently underway. 
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